Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
SC semaglutide 2.4 mg (14.9% at 68 wk) remains the benchmark for approved GLP-1 monoagonist therapy
Nat Prod Bioprospect (2020) 10:43143
2007;21 Suppl 1:31-8
Other considerations include if this class of medications is dropped from coverage, patients on the drugs will need to find other ways to pay for it if they want to continue, the affordability and availability of the medications, and what will the long-term impact be if patients stop taking the medications suddenly
Wegovy, Ozempic, Zepbound)
US$ 20.10
US$ 22.37
US$ 25.07
US$ 26.43
US$ 23.46
